Morphic Holding, Inc. (31Y.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 03:29PM CEST. Market open.
| Previous close | 27.60 |
| Open | 27.20 |
| Bid | 27.00 x N/A |
| Ask | 28.20 x N/A |
| Day's range | 27.00 - 27.20 |
| 52-week range | 18.50 - 56.50 |
| Volume | |
| Avg. volume | 4 |
| Market cap | 1.371B |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.34 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 100.50 |
Simply Wall St.Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GuruFocus.com
Morphic Holding Inc (MORF) Q1 2024 Earnings: A Detailed Review
Insights into Financial Performance and Strategic Developments
GlobeNewswireMorphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasda
© 2024 Yahoo. All rights reserved.